PFA Isn’t the Challenge Anymore,
Precision Is
PFA Isn’t the Challenge Anymore, Precision Is
Pulsed Field Ablation (PFA) dominated the conversation at HRS (Heart Rhythm Society) 2026. The energy modality has clearly moved beyond early validation and into widespread adoption, with strong clinical data and accelerating momentum across the electrophysiology community.
Recent late-breaking trials presented at HRS showed that PFA can significantly reduce arrhythmia recurrence compared to drug therapy, reinforcing its role as a frontline treatment for atrial fibrillation. At the same time, new datasets continue to highlight strong procedural success rates and favorable safety profiles across emerging PFA systems.
PFA works. That’s no longer in question.
But beneath the surface, a different conversation starts to take shape.
The question is no longer “Does PFA work?”
It’s becoming: “How do we perform PFA with confidence, consistency, and control?”
Clinical Breakthroughs Are Raising the Bar
The latest clinical data presented at HRS reinforces just how far PFA has come.
A late-breaking trial showed that using PFA as a first-line therapy significantly reduced arrhythmia recurrence compared to drug therapy, marking a major shift in how atrial fibrillation may be treated going forward. At the same time, new datasets continue to demonstrate high durability and procedural consistency, with some studies reporting freedom from atrial fibrillation in up to 90% of patients at one year and very low complication rates.
Longer-term data further reinforces that these outcomes are sustained over time, with PFA maintaining effectiveness comparable to or better than traditional thermal ablation approaches.
But as outcomes improve, expectations rise.
PFA is Expanding Beyond the Hospital
Another emerging theme from HRS is the potential shift of electrophysiology procedures into ambulatory surgery centers (ASCs). As PFA enables shorter, more efficient procedures with reduced reliance on general anesthesia, outpatient settings are becoming increasingly viable.
But this shift introduces new challenges. ASCs operate with leaner infrastructure, fewer imaging redundancies, and greater variability across operators and environments. In these settings, there is less margin for uncertainty, and less time to correct it. ‘You are working on an island’.
This is a new setting where a low fluro or fluro-less procedure is desirable, thus sensor-enabled ICE catheters and other OEM devices that integrate electromagnetic position-tracking technology may become a more prominent part of the ASC procedural ecosystem.
The Mapping Debate Misses the Real Issue
One of the most debated topics at HRS was whether mapping is still required in PFA procedures.
Some advocate for eliminating it to improve efficiency. Others strongly defend its role in ensuring procedural success.
But this debate may be missing the bigger issue.
When mapping fails, it’s often not because the concept is flawed,
This reframes the conversation: it’s not “mapping vs. no mapping.” It’s “how do we ensure the information guiding the procedure is accurate?”
PFA Is an Ecosystem
Another clear takeaway from HRS is that PFA success is not defined by a single device or technology.
It’s an ecosystem.
Imaging, therapy delivery, mapping, all need to work together. Today’s workflows often combine multiple systems, each contributing a piece of the overall solution.
The 2026 HRS scientific statement reinforces this reality, highlighting the importance of integrating technologies into cohesive procedural workflows.
“The future of PFA will not be defined by individual components but by how well the ecosystem works together.” And at the center of that ecosystem is a foundational requirement: accurate, dependable tracking that OEM device manufacturers can build upon when designing the next generation of cardiac platforms.
So…..How do we perform PFA with confidence, consistency, and control?
How do we ensure the information guiding the procedure is accurate?
There is growing interest among OEM device manufacturers in integrating electromagnetic position-sensing technology into their devices, reflecting a broader industry trend toward sensor-enabled OEM products
Electromagnetic position-tracking technology is impedance-independent and provides repeatable positional measurements, technical characteristics that OEM device developers can leverage when designing devices for energy-delivery applications.
As procedures become faster and less reliant on traditional imaging, this level of positional confidence becomes even more important.
Looking Ahead
PFA has changed the trajectory of electrophysiology. That much is clear. But as the field matures, the focus shifts from capability to confidence.
The next phase of innovation will center on:
- Improving procedural consistency
- Reducing variability across operators
- Enabling simplified workflows without sacrificing control
And at the core of all three is a simple but critical requirement: Knowing exactly where you are at all times.
Because in the end, delivering energy is only part of the equation.
Delivering it accurately, repeatedly, and with confidence is what defines the future of PFA.
NDI is a Canadian manufacturer of precision measurement technology supplied to OEM medical device companies. NDI does not market a finished medical device for cardiac ablation, navigation, or imaging. Clinical performance, intended use, and regulatory clearance of any finished device incorporating NDI technology are the responsibility of the OEM manufacturer.
The Next Phase of PFA Is Built on Precision Tracking
Aurora EM tracking gives OEM cardiology teams continuous 3D catheter localization, the positional foundation for designing PFA platforms with the consistency and control the field expects.